<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18417839</article-id><article-id pub-id-type="pmc">2636102</article-id><article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_3_258_40379</article-id><article-id pub-id-type="pmid">18417839 </article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Intra-cameral injection of Bevacizumab		(Avastin) to treat anterior chamber		neovascular membrane in a painful		blind eye</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Agarwal</surname><given-names>Manisha</given-names></name><degrees>MS, DNB</degrees></contrib><contrib contrib-type="author"><name><surname>Dubey</surname><given-names>Suneeta</given-names></name><degrees>MS</degrees></contrib></contrib-group><aff>Vitreoretina Services (MA), Glaucoma Services (SD), Dr. Shroff&#x02032;sCharity Eye Hospital, 5027, Kedar Nath Road, Daryaganj.New Delhi, India.</aff><author-notes><corresp id="cor1">Correspondence to Dr. Manisha Agarwal, Dr. Shroff ?s Charity EyeHospital, 5027, Kedar Nath Road, Daryaganj, New Delhi - 110 002,India. Email: <email>agarwalmannii@yahoo.co.in</email></corresp></author-notes><pub-date pub-type="ppub"><season>May-Jun</season><year>2008</year></pub-date><volume>56</volume><issue>3</issue><fpage>258</fpage><lpage>259</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions></article-meta></front><body><p>Dear Editor,</p><p>We read with great interest the article titled &#x02033;Intra-cameralinjection of bevacizumab (Avastin) to treat anteriorchamber neovascular membrane in a painful blind eye&#x02033; byRaghuram <italic>et al</italic>.<xref ref-type="bibr" rid="ref1">1</xref></p><p>We would like to share our experience of an interventionalcase series in which 14 patients of diabetic retinopathy(DR) and vascular occlusions complicated with neovascularglaucoma and raised intraocular pressure (IOP) causingpain and circum-corneal congestion were included. All thesepatients were treated with intra-vitreal (1.25 mg/0.05 ml)and intra-cameral (0.25 mg/0.02 ml) bevacizumab (Avastin)injection after an informed consent from the patients. Therewas regression of iris neovascularization (NVI) in 8 days (1to 14 days) on an average [<xref ref-type="fig" rid="F1">Fig. 1</xref>]. Nine patients underwentphaco-trabeculectomy with intraocular lens implantation(those with significant cataract) or trabeculectomy followedby pan-retinal photocoagulation (PRP) to ablate the ischemicretina. Four patients underwent PRP and medical managementof glaucoma and one was lost to follow-up. On an averagefollow-up of 6 months (range 3 to 12 months), two patientsshowed more than two-line improvement in vision and the restall had stabilization of vision. All patients showed stabilizationof IOP with well-formed filtering blebs.</p><p>Two patients had a recurrence of iris NVI after 14 and 16 weeksof Avastin injection, respectively, presenting with hyphema[<xref ref-type="fig" rid="F2">Fig. 2</xref>]. Intra-cameral injection of Avastin had to be repeatedin both these cases. Both cases at their last follow-up at 8months were stable with no evidence of recurrence of NVI orneovascularization of the angle (NVA).</p><p>We have used intra-cameral Avastin in a dose of 0.25 mg/0.02 ml in comparison to 1 mg/0.04 ml used in the article byRaghuram <italic>et al</italic>.<xref ref-type="bibr" rid="ref1">1</xref> and found this low dose to be as effectivein regressing NVI and NVA. In our cases of DR and vascularocclusions, the NVI and NVA were caused secondary to theproduction of VEGF from the ischemic retina;<xref ref-type="bibr" rid="ref2">2</xref> and we targetedthe source of VEGF by intra-vitreal Avastin and ablating theischemic retina with laser photocoagulation thus trying toavoid a recurrence of NVI/NVA. However, in comparison tothe case reported by Raghuram <italic>et al</italic>.,<xref ref-type="bibr" rid="ref1">1</xref> we had a recurrence intwo cases probably because of active production of vascularendothelial growth factor (VEGF) from the ischemic cells incomparison to cells dying without ischemia in a phthisical eye.The advantages of intra-cameral Avastin were - rapid regressionof NVI avoiding a delay in surgery to normalize IOP in thesecases with already compromised perfusion to optic nerve headsecondary to diabetic retinopathy and vascular occlusions, andincreasing the success rate of glaucoma surgery by avoidingintra-operative bleed.</p><p>To conclude, intra-cameral Avastin in lower doses waseffective in causing regression of NVI/NVA which may betemporary in cases of DR and vascular occlusions with anactive production of VEGF; and a more long-term regressionin these cases may require targeting the production ofVEGF from the posterior segment by additional intra-vitrealAvastin,<xref ref-type="bibr" rid="ref3">3</xref> laser photocoagulation or cryopexy. Potentialsystemic side-effects have been reported with intra-vitrealAvastin injection and we need to weigh the risk-benefit ratiobefore using this drug.</p></body><back><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghuram</surname><given-names>A</given-names></name><name><surname>Saravanan</surname><given-names>VR</given-names></name><name><surname>Narendran</surname><given-names>V</given-names></name></person-group><article-title>Intra-cameral injectionof Bevacizumab (Avastin) to treat anterior chamber neovascularmembrane in a painful blind eye</article-title><source>Indian J Ophthalmol</source><year>2007</year><volume>55</volume><fpage>460</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">17951906</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aiello</surname><given-names>LP</given-names></name><name><surname>Avery</surname><given-names>RL</given-names></name><name><surname>Arrigg</surname><given-names>PG</given-names></name><name><surname>Keyt</surname><given-names>BA</given-names></name><name><surname>Jampel</surname><given-names>HD</given-names></name><name><surname>Shah</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor in ocular fluid of patientswith diabetic retinopathy and other retinal disorders</article-title><source>N Engl J Med</source><year>1994</year><volume>331</volume><fpage>1480</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7526212</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avery</surname><given-names>R</given-names></name><name><surname>Pearlman</surname><given-names>J</given-names></name><name><surname>Pieramici</surname><given-names>D</given-names></name><name><surname>Rabena</surname><given-names>M</given-names></name><name><surname>Castellarin</surname><given-names>A</given-names></name><name><surname>Nasir</surname><given-names>M</given-names></name><etal/></person-group><article-title>Intravitreal bevacizumab (Avastin) in the treatmentof proliferative diabetic retinopathy</article-title><source>Ophthalmology</source><year>2006</year><volume>113</volume><fpage>1695</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">17011951</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p>(A, B) Early and late phases of anterior segment fluorescein angiography showing dye leakage from iris neovascularization prior tointra-cameral Avastin injection. (C, D) Early and late phases of anterior segment fluorescein angiography showing reduced dye leakagefrom iris neovascularization after intra-cameral Avastin injection</p></caption><alt-text>Figure 1</alt-text><graphic xlink:href="IndianJOphthalmol-56-258-g001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Recurrence of iris neovascularisation presenting as hyphema</p></caption><alt-text>Figure 2</alt-text><graphic xlink:href="IndianJOphthalmol-56-258-g002"/></fig></floats-group></article>